A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

NCT06161571 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

700

Enrollment

INDUSTRY

Sponsor class

Conditions

NASH/MASH
NAFLD/MASLD

Interventions

DRUG: Efruxifermin
DRUG: Placebo

Sponsor

Akero Therapeutics, Inc